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The use of new technologies in complex treatment of chronic parenchymal sialadenitis. The use of 
vasaprostannucellary form in complex treatment of patients with chronic parenchymatoussialadenitis in a stage 
of an aggravation in the field of amazed salivary gland renders good therapeutic effect, which is proved by 
clinical data and results of reografic and bioснemical researches (lactoferrin concentration, 
middlemolecularpeptids and sum of primary and secondary products of hyperoxide acidification lipids, basis 
of Shiff). 
 
Keywords: Chronic parenchymal sialadenitis, Nanotechnology, Vasaprostan, Products of lipid peroxidation.Treatment of chronic 
parotitis with the using of nanotechnologies. 
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1. Introduction 
The use of the mycelian form of vazaprostan in the complex treatment of patients with 
parenchymatoussialadenitis in the period of exacerbation in the affected area of a salivary gland provides good 
therapeutic effect that is proved by clinical data and results of rheographic and biochemical studies (lactoferrin level, 
MMP and total primary and secondary products of lipid peroxidation). 
Keywords: chronic parenchymatous sialadenitis, nanotechnology, vazaprostan, lactoferrin, products of lipid 
peroxidation, midmolecular peptides.  
Treatment for chronic parotitis with using nanotechnology. 
Chronic parenhymatous sialadenitis accounts 41,5-67,9 % of cases among the diseases of salivary glands [1]. 
Chronic course of parenhymatous sialadenitis with frequent severe exacerbations reduces the quality of life of 
patients, results in steady dysfunction of the salivary glands, the principal of which is the participation in the 
maintenance of homeostasis of the mouth and digestive tract as well as the whole body [2]. In the pathogenesis of 
chronic parenchymatous sialadenitis microcirculation disturbance plays an important role, so the search for new 
methods of treatment continues, contributing to improve it Varshavskiy and Guberskaya [3]. With this purpose 
vazaprostan is widely used in various fields of medicine and it has multifunctional action: provides metabolic, 
antioxidant, immunomodulatory, anti-inflammatory and cytoprotective action by combining the effects of various 
cardiovascular drugs (vasodilators, disaggregantsand angioprotectors) [4].  
In the Republic of Kazakhstan under the guidance of RK NAS academician Gilmanov M.K. there was created 
mycelian (liposomal) form of a drug delivery based on nanotechnology. Nanocapsules having no analogues, sized 
less than 1 µm and  based on vegetable phosphotidylinositol were obtained [5]. Methods of treatment of patients with 
different pathologies with using mycellia, "loaded" by medicinal preparations have been developed and successfully 
used [6, 7]. The objective of the work was to study the efficacy of applying mycelian form of delivering vazaprostan 
in the complex treatment for chronic parenchymatous sialadenitis during the period of exacerbation. 
 
2. Material and Methods of Studying 
Mycelianform of vazaprostan was prepared in the laboratory of the structure and regulation of the enzymes of 
M.A. Aitkhozhin Institute of Molecular Biology and Biochemistry (the head is Doctor of Biology, Professor, RK 
NAS Academician Gilmanov M.K). To download medicinal preparations there was applied a mycelium property to 
be open in the hydrophobic phase (Figure 1), followed by "collapsing" when transferred into the aqueous phase, thus 
capturing the downloaded substance, in particular, vazaprostan (Figure 2).The transdermal form of mycelia with 
vazaprostan, prepared by this method, is quite inert, neutral and stable during the storage (up to 1   year). 
Under the observation there were 91 patients (75 - females 16 – males, aged 20 to 63 years) with chronic 
parenchymatous parotitis in the period of exacerbation. All patients underwent conventional complex treatment such 
as the prescribed antibiotic, detoxification, restorative therapy and physiotherapy. Depending on the nature of the 
local treatment, the patients were divided into two groups: basic (47 patients) and comparison (44 persons). Mycelian 
form of vazaprostan in the form of an ointment was given to the patients of the main group for local use. It was 
applied to the skin in the affected parotid salivary gland (PSG) area and spread evenly on the skin surface by light 
rubbing motions one dose per day in the morning. The duration of the treatment was 10 days. In the comparison 
group there were used compresses with 30% dimethyl sulfoxide solution to the area of the salivary gland for 20-30 
minutes during 10 days as local treatment.  
 
 
 
Fig-1. Electron microscopy. medicinal substance in the 
hydrophobic phase. 
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Fig-2. Scheme of loading mycelia by (1 – mycelium, 2- 
vazaprostan, 3 - loaded mycelium). 
 
For using in the treatment of patients with chronic parenchymatous sialadenitis at clinics a mycelian form of 
vazaprostan was approved by Ethics Commission of S.D. Asfendiyarov Kazakh National Medical University 
(protocol № 4 of 11.03.2010 y.) and by decision of Pharmacological Centre of Almaty of 12.03.2010 (protocol № 
05-10).  
At admission to the hospital and in the dynamics of treatment the rheographic and biochemical studies were 
carried out to all patients. Biochemical studies were conducted in the practically healthy persons (23 males) and 57 
patients in the dynamics: at admission, after 7, 10, and 14 days. The level of  lactoferrin (LF), midmolecular peptides 
(MMP) and the state of lipid peroxidation (LPO) in the secretion, taken from the excretory duct of the parotid 
salivary glands with a help of a polyethylene catheter from 8 to 10 a.m. on an empty stomach were studied. 
Determining the concentration of LF was conducted by using enzyme multiplied immunoassay with a help of EJA 
(Germany) diagnostic kits on the"Antos 2010" (Austria) diagnostic system. LF concentration was expressed as ng / 
ml. MMP level was determined spectrophotometrically by ultraviolet light at a wave length of 254 nm and expressed 
in conventional units (c.u.) [8]. Lipid peroxidation (LPO) intensity was studied by determining the total primary 
(TPP) and secondary products (TSP) and Schiff bases (SB) [9]. Conventional units were the units of measurement. 
Rheograms were recorded according to tetrapolar technique on the rheograph 4RG-2M and electrocardiograph was 
used as a recording device.  
 
3. Results of the Study 
Complex treatment of patients with chronic parenchymal in acute sialadenitis with using mycelian form of 
vazaprostan showed that the dynamics of clinical improvement of clinical picture in patients of the main group was 
faster towards patients of comparison group, which resulted in a more rapid disappearance of pain, normalization of 
gland sizes. Thus, stopping  purulent discharge from the duct of the parotid salivary gland in the main group patients 
occurred on average on the 4,2  0,23 day, and in the comparison group- much later - on the 5,4  0,17  day (P <0.01 
). The average number of bed-days of the main group patients was 7, 0 ± 0, 22, in the comparison group patients 
were discharged much later-on the 10,1 ± 0,21  day (P <0.001). 
 
Table-1. Dynamics of changes in the level of lactoferrin (ng/ml) in the saliva of patients with chronic parenchymatous sialadenitis in 
the period of exacerbation, symptomatic, and advanced stages in the treatment by mycelian form of vazaprostan. 
Groups of 
patients 
Terms of observation, days 
1
st
 7
th
 10
th
 14
th
 
The 1st main 
group 
 
2006,7±16,42     1348,6±12,51       1014,2±12,30           
 Р<0,001                   Р<0,001                                 
 Р1>0,05                   Р1<0,001                  Р1<0,001            
The 1st 
comparison 
group 
2006,7±17,12    1631,90±15,22  1287,1±13,71          1031,7±14,17 
 Р<0,001            Р<0,001                   Р<0,001 
 
Practically 
healthy persons,  
n = 17 
1010,2±21,1 
 
Note: P - reliability of difference in the indices at different terms of treatment (previous and next) of one group of patients; P1 - reliability of 
difference in the indices of the main and comparison groups at the same term of treatment. 
 
Comparative analysis of biochemical test results of PSG secretion confirmed that on using  mycelian form of 
vazaprostan the normalization of indices occurred faster in the group of patients being conducted the complex 
treatment with mycelian form of vazaprostan (Tables 1 and 2). 
Thus, the level of lactoferrin in practically healthy persons was 1010,2 ± 21,1 ng / ml, but in chronic acute 
parenchymatous sialadenitis ( in the main and as well as in the comparison group) on the first day of visiting clinic it 
was  2006,7 ± 16.42 ng / ml (Table 1), testifying the inflammatory process in the affected gland. 
As a result of the treatment with using vazaprostan a normalization of   lactoferrin concentration occurred much 
faster in the main group than in the comparison one. So, in the main group lactoferrin level (1348,6 ± 12,51 ng / ml) 
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decreased by 32.8% on the 7
th
 day  as compared with the baseline values of lactoferrin, although there was still high, 
and there was a normalization of level (1014,2 ± 12,3 ng / ml, P> 0,05) already on the 10
th
 day . In the comparison 
group dynamics of lactoferrin values normalization occurred only on the 14
th
 day (Table 1). Fast dynamics of 
reducing the level of lactoferrin in the main group of patients showed a significant decrease in the inflammatory 
activity under the effect of the mycelian form of vazaprostan. 
At admission to the hospital LPO indicators of parotid salivary glands secretion in patients significantly 
exceeded the normal values (Table 2), indicating a high rate of oxidation-restoration processes during exacerbation 
of chronic parenchymatous sialadenitis. On the day of visiting a clinic the level of TPP was significantly higher than 
normal ones (0,92 ± 0,057 c.u.), (P <0,05) in patients of the main group. On the 7
th
 day, the level of TPP decreased 
by 0.25 c.u., that accounted 27,2% (P <0,01), on the 10 
th
 day  there was a normalization of data. In the comparison 
group dynamics of TPP values  normalization was slower and only on the 14
th
 day there were registered the levels 
corresponding to the normal data (Table 2). 
 
Table-2. Dynamics of changing indices of LPO and MMP level (c.u.) in the PSG secretion in patients with chronic parenchymatous 
sialadenitis in the period of exacerbation, symptomatic, and advanced stages in the treatment by mycelian form of vazaprostan. 
Groups of 
patients 
Terms of 
studying 
Biochemical data  
TPP TSP ShB MMP 
Main group 
 
 
 
Comparison 
group 
1
st
 day 
 
0,92±0,057 
P<0,001 
Р1>0,05 
0,91±0,058 
P<0,001 
 
0,87±0,029 
P<0,001 
Р1>0,05 
0,87±0,027 
P<0,001 
 
0,79±0,033 
P<0,001 
Р1>0,05 
0,79±0,031 
P<0,001 
 
0,089±0,0005 
P<0,001 
Р1>0,05 
0,088±0,0004 
P<0,001 
 
Main group 
 
 
 
Comparison 
group 
7 
th
 day 
 
 
0,67±0,039 
P<0,05 
Р1<0,05 
0,79±0,034 
P<0,01 
0,65±0,014 
P<0,05 
Р1<0,05 
0,71±0,015 
P<0,01 
0,58±0,027 
P<0,05 
Р1<0,05 
0,69±0,025 
P<0,001 
0,063±0,0002 
P<0,001 
Р1<0,001 
0,078±0,0002 
P<0,001 
Main group 
 
 
 
Comparison 
group 
10
 th
 day 
0,52±0,033 
P>0,05 
Р1<0,05 
0,66±0,037 
P<0,05 
0,55±0,022 
P>0,05 
Р1<0,01 
0,65±0,017 
P<0,05 
0,47±0,036 
P>0,05 
Р1<0,01 
0,62±0,022 
P<0,01 
0,040±0,0003 
P>0,05 
Р1<0,001 
0,062±0,0002 
P<0,001 
Main group 
 
 
Comparison 
group 
 
14
th
 day 
 
0,51±0,04 
P>0,05 
Р1>0,05 
0,53±0,05 
P>0,05 
0,55±0,032 
P>0,05 
Р1>0,05 
0,56±0,033 
P>0,05 
0,47±0,033 
P>0,05 
Р1>0,05 
0,48±0,033 
P>0,05 
0,040±0,0002 
P>0,05 
Р1>0,05 
0,042±0,0003 
P>0,05 
Practically 
healthy persons 
 0,51±0,05 0,55±0,041 0,47±0,037 
0,040±0,0002 
Note: P - reliability of difference in the indices relative to normal values; P1 – reliability of difference in the indices of patients of the 1st main group 
and the 1st comparison group at  the same terms of treatment. 
 
At admission to the hospital the values of total secondary products (TSP) in the main group of patients exceeded 
the indices by 0.32 c.u. (P <0,001). On the 7
th
 day the level of TSP in the main group significantly decreased by 0.22 
c.u. (26.4%), accounting 0,65 ± 0,014 c.u., and the normalization of the indices occurred on the 10
th
 day of treatment. 
In the comparison group changes dynamics was less marked: TSP level decreased by 0.16 c.u. (18.4%) on the 7
th
 day 
, by 0.22 c.u.(25.3%)-on the 10
th
 day, and the normalization values of TSP occurred on the 14
th
 day (0,56 ± 0,033 
c.u.). 
At the admission to the clinic the values of the final products of lipid peroxidation - Schiff bases in the main 
group of patients exceeded the standard ones by 0.32 c.u. (68.1%). As a result of the complex treatment the ShB 
level decreased, resulting in normalizing   metabolic processes and restoring the structural integrity of a cell. On the 
7
th
 day in the main group while using mycelian form of vazaprostan it decreased by 0.21c.u. (26.6%) and on the 10
th
 
day Sh.B. values were normalized. In patients of comparison group Sh.B values became normal only on the 14
th
 day. 
At visits to the clinic MMP level in the saliva of patients accounted 0,089 ± 0, 0005c.u. (P <0,001) (Table 2). It 
indicated an accumulation of secondary metabolites in the saliva of patients due to the formation of tissue breakdown 
products resulting from changing metabolism towards catabolism, as well as the accumulation of toxins and waste 
products of infectious agents. On the 7
th
 day MMP values in the main group were reduced by 29.2%, on the 10
th
 day -
by 55.1%, corresponding to normal ones, whereas in the control group they were 12.4% and 29.6% respectively and 
only on the 14
th
 day normalization of the level occurred. 
 Analysis of the rheographic studies results showed that on the first day of treatment of patients in the clinic there 
were signs of microcirculation disturbance of the affected salivary glands: the ascending part of the rheogram was 
shallow; its peak was as a flattened plateau, rheogram amplitude lowered. The median rheographic index (RI) in the 
practically healthy individuals was 0, 07 ± 0,003 Om, but in patients - 0, 02 ± 0,001 Om. As a result of the treatment 
there was a positive dynamics of rheographic indicators, which occurred more rapidly in the main group of patients 
than in the comparison one. By the end of the therapy there was observed the improvement of quality of rheographic 
curve and its amplitude increased. On the 7
th
 day of treatment RI of rheogram was 0, 05 ± 0.003 Om in patients of 
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the main group, whereas those of the comparison group - 0, 04 ± 0.002 Om(P <0.05). On the 14
th
 day of the study, 
the quantitative and qualitative rheogram indicators of the main group of patients already reflect the data typical for 
the stage of remission (RI was equal to 0,07 ± 0,003 Ohm, P> 0,05), and in patients of the comparison group  RI 
normalized only on the 18
th
 day  of observation (RI was 0,066 ± 0,003 Om (P> 0,05). Our data of the rheographic 
studies showed the improvement of blood flow in the vessels of the parotid salivary gland during the treatment 
process, besides on  using  the mycelian form of vazaprostan it  occurred much faster than in the groups of 
comparison. 
 
4. Discussion 
The carried out studies have shown that the use of mycelian form of vazaprostan in the complex treatment of 
patients with chronic parenchymatous sialadenitis in the period of exacerbation (in comparison with the results of the 
treatment in the control group, where Dolobene gel or a 30% solution of dimethyl sulfoxide were used) significantly 
faster improves the clinical state of patients, reduces the number of bed-days on average by 3,0 ± 0,16 days, increases 
the duration of remission (in the main group - 13,8 ± 0,3 months, in the comparison groups - 7,1 ± 0,1 months, P 
<0,001). 
During the exacerbation period of chronic parenchymatous sialadenitis (P <0.001) the level of lactoferrin (up to 
2006,7 ± 17,12 ng / ml), the total primary products of lipid peroxidation (up to 0,91 ± 0,058c.u.), the total secondary 
products (up to 0,87 ± 0,027c. u.), Schiff bases (up to 0,79 ± 0,031 c.u.), midmolecular peptides (up to 0,088 ± 
0,0004 c.u.) significantly increased. Transdermal use of mycelian form of vazaprostan in the complex treatment of 
patients with chronic parenchymatous sialadenitis in the stage of exacerbation resulted in a more rapid normalization 
of lactoferrin level in the saliva, LP indices (total primary products, total secondary products and Schiff bases) and 
midmolecular peptides (characterizing toxins discharge with salivary gland secretion) than when using a compress 
with 30% solution of Dimexidum or Dolobene gel. It showed a more marked (relative to the comparable drugs) anti-
inflammatory, antioxidant properties of the drug, its ability to reduce the level of toxins and secondary metabolites in 
the saliva. 
During exacerbation of chronic parenchymatous sialadenitis there were observed the microcirculatory disorders 
of  salivary glands, which resulted in reducing the rheographic index of a rheogram to 0,02 ± 0,003 Om (P <0.001). 
The results of the rheographic studies on using vazaprostan showed the improvement of blood flow in the vessels of 
the parotid salivary gland, the increase of their elasticity, the reduction of their tonic tension in the treatment process, 
which was explained by lowering the inflammatory process, and it happened faster than in the comparison groups. 
 
5. Conclusions 
Mycelian form of vazaprostan has multifaceted effects: antioxidant and anti-inflammatory actions, reducing the 
level of toxins and secondary metabolites in the saliva of patients and improving microcirculation of the affected 
salivary glands tissues. 
Micelian form of vazaprostan may be recommended for using in the complex treatment of patients with chronic 
parenchymatous sialadenitis in the period of exacerbation. 
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